Published in Trends Pharmacol Sci on March 10, 2012
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem (2013) 1.03
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
NIH TRND program: successes in preclinical therapeutic development. Trends Pharmacol Sci (2012) 0.87
Mouse models of human disease: An evolutionary perspective. Evol Med Public Health (2016) 0.79
Parallel universes of Black Six biology. Biol Direct (2014) 0.79
The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Res Notes (2014) 0.76
A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles. Nano Today (2014) 0.75
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics (2015) 0.75
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. PLoS One (2016) 0.75
Does age matter? The impact of rodent age on study outcomes. Lab Anim (2016) 0.75
A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. J Ovarian Res (2015) 0.75
Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. Med Res Rev (2016) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
The meaning of translational research and why it matters. JAMA (2008) 20.37
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Translational research: crossing the valley of death. Nature (2008) 5.02
Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol (2000) 4.58
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov (2011) 3.42
Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23
Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res (1996) 3.11
ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov (2003) 3.00
Drug discovery in jeopardy. J Clin Invest (2006) 2.78
Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal (2007) 2.76
The future of drug development: advancing clinical trial design. Nat Rev Drug Discov (2009) 2.68
The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol (2010) 2.63
Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer (2007) 2.52
The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol (1984) 2.52
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40
Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov (2011) 2.32
Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol (2009) 2.14
Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A (2011) 2.12
Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov (2011) 2.12
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Theranostics: combining imaging and therapy. Bioconjug Chem (2011) 2.01
Why is cancer drug discovery so difficult? Nat Rev Drug Discov (2006) 1.90
Traversing the valley of death: a guide to assessing prospects for translational success. Sci Transl Med (2009) 1.81
Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer (1999) 1.79
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev (2010) 1.64
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther (2006) 1.61
Mouse models of cancer. Annu Rev Pathol (2011) 1.59
Optimizing combination chemotherapy by controlling drug ratios. Mol Interv (2007) 1.55
The impact of mergers on pharmaceutical R&D. Nat Rev Drug Discov (2011) 1.54
What's wrong with our cancer models? Nat Rev Drug Discov (2005) 1.52
Why we're losing the war on cancer (and how to win it). Fortune (2004) 1.43
Anticancer drug development: the grand challenges. Nat Rev Drug Discov (2010) 1.42
Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol (2011) 1.41
Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun (2011) 1.41
The rise and rise of drug delivery. Nat Rev Drug Discov (2005) 1.39
Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol (2003) 1.38
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
The APL paradigm and the "co-clinical trial" project. Cancer Discov (2011) 1.33
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol (2011) 1.29
Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett (2011) 1.27
Clinical applications of the histoculture drug response assay. Clin Cancer Res (1995) 1.27
Phase 0 clinical trials: an answer to drug development stagnation? J Clin Oncol (2009) 1.26
An Investigation of the Laws of Disinfection. J Hyg (Lond) (1908) 1.25
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res (2007) 1.25
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des (2003) 1.24
Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem (1998) 1.24
Culturing at atmospheric oxygen levels impacts lymphocyte function. Proc Natl Acad Sci U S A (2005) 1.23
19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev (2000) 1.19
Molecular imaging of hypoxia. J Nucl Med (2011) 1.15
Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer (2010) 1.13
Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med (2009) 1.13
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res (2009) 1.12
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res (1999) 1.12
Applications of molecular imaging in drug discovery and development process. Curr Pharm Biotechnol (2011) 1.11
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett (2011) 1.10
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol (2010) 1.08
Imaging pH with hyperpolarized 13C. NMR Biomed (2011) 1.08
He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst (1990) 1.03
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol (2004) 1.03
Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother (2011) 1.03
Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem (2011) 1.03
The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul (2009) 1.01
Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov (2009) 1.01
Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem (2010) 0.99
Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzyme Regul (1999) 0.99
Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet (2000) 0.95
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther (2008) 0.94
Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res (2011) 0.94
Analysis: overcoming the "valley of death": mouse models to accelerate translational research. Diabetes Technol Ther (2006) 0.91
The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line. Acta Biochim Pol (2005) 0.89
The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter. Int J Radiat Oncol Biol Phys (2008) 0.89
Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med (2003) 0.88
Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther (2010) 0.87
Wireless implantable electronic platform for chronic fluorescent-based biosensors. IEEE Trans Biomed Eng (2011) 0.87
We fought cancer...and cancer won. Newsweek (2008) 0.87
Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res (1997) 0.86
Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv (2010) 0.86
Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development. Curr Med Chem (2011) 0.86
Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol (2005) 0.86
The assessment of microvascular flow and tissue perfusion using ultrasound imaging. Proc Inst Mech Eng H (2010) 0.85
Implantable semiconductor biosensor for continuous in vivo sensing of far-red fluorescent molecules. Opt Express (2010) 0.84
Therapeutic drug monitoring in cancer chemotherapy. Bioanalysis (2010) 0.83
Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs. Anticancer Drugs (2010) 0.83
Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract (2007) 0.82
A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol (2000) 0.82
Long-term response to crisnatol mesylate in patients with glioma. Invest New Drugs (1997) 0.81
Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. Anticancer Drugs (2009) 0.80